Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.64 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | ITK | Q08881 | 3/20 | 0.57 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952273 | 0.90 | KDM4E (0.68) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL8373049 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL951202 | 0.89 | FLT3 (0.67) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL950058 | 0.87 | RAB9A (1.00) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL954666 | 0.86 | KDM4E (0.64) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL7846799 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL5945685 | 0.85 | RAB9A (0.60) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL26715333 | 0.84 | RAB9A (0.83) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL20267080 | 0.84 | RAB9A (0.75) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL950894 | 0.82 | NPC1 (0.68) | SMN1; SMN2RAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109642-A1 | USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR | 常州大学 | 2024-05-30 | — | — | WO | disclosed |
| CN-117229217-A | Allosteric modulator of adrenergic receptor functional activity, preparation method and application thereof | 常州大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20110038850-A1 | G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2011-02-17 | — | — | US | disclosed |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1254115-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | Bristol-Myers Squibb Company (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058869-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | SMN1; SMN2 2680/4885RAB9A 2782/4885NPC1 551/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | SMN1; SMN2 2680/4885RAB9A 2782/4885NPC1 551/4885 |
| US-20110038850-A1 | G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders | BRS3, GPR3, GABRA3 | SMN1; SMN2 3558/4885RAB9A 840/4885NPC1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.